Aequus Pharmaceuticals Inc Market Cap ($479.73K)
Market Cap & Net Worth: Aequus Pharmaceuticals Inc (AQS)
Aequus Pharmaceuticals Inc market cap. Aequus Pharmaceuticals Inc (V:AQS) has a market capitalization of $479.73K (CA$663.17K) as of November 1, 2026. Listed on the V stock exchange, this Canada-based company holds position #31092 globally and #1644 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aequus Pharmaceuticals Inc's stock price CA$0.01 by its total outstanding shares 132634431 (132.63 Million). Also see cash efficiency ratio of Aequus Pharmaceuticals Inc for how efficiently the company converts equity into cash flow.
Aequus Pharmaceuticals Inc Market Cap History (2015–2026)
Aequus Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows change from $59.49 Million to $479.73K (-36.46% CAGR). Check AQS stock price and chart for real-time trading data and today's change.
Aequus Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aequus Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Aequus Pharmaceuticals Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.64x
Aequus Pharmaceuticals Inc's market cap is 1.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $23.03 Million | $701.63K | -$4.81 Million | 32.82x | N/A |
| 2017 | $25.43 Million | $1.14 Million | -$3.88 Million | 22.31x | N/A |
| 2018 | $14.87 Million | $1.41 Million | -$2.80 Million | 10.55x | N/A |
| 2019 | $11.99 Million | $1.63 Million | -$3.11 Million | 7.35x | N/A |
| 2020 | $11.51 Million | $2.59 Million | -$1.05 Million | 4.44x | N/A |
| 2021 | $11.03 Million | $2.71 Million | -$1.81 Million | 4.06x | N/A |
| 2022 | $3.36 Million | $1.38 Million | -$3.21 Million | 2.43x | N/A |
| 2023 | $2.40 Million | $254.90K | -$2.96 Million | 9.41x | N/A |
| 2024 | $959.46K | $584.24K | -$2.18 Million | 1.64x | N/A |
Competitor Companies of AQS by Market Capitalization
Companies near Aequus Pharmaceuticals Inc in the global market cap rankings as of November 1, 2026. Also see total assets of Aequus Pharmaceuticals Inc for a full breakdown of the balance sheet.
Key companies related to Aequus Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Aequus Pharmaceuticals Inc (2015–2026)
Market capitalization of Aequus Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Aequus Pharmaceuticals Inc's market cap moved from $59.49 Million to $ 479.73K, with a yearly change of -36.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$479.73K | 0.00% |
| 2025 | CA$479.73K | -50.00% |
| 2024 | CA$959.46K | -60.00% |
| 2023 | CA$2.40 Million | -28.57% |
| 2022 | CA$3.36 Million | -69.57% |
| 2021 | CA$11.03 Million | -4.17% |
| 2020 | CA$11.51 Million | -4.00% |
| 2019 | CA$11.99 Million | -19.35% |
| 2018 | CA$14.87 Million | -41.51% |
| 2017 | CA$25.43 Million | +10.42% |
| 2016 | CA$23.03 Million | -61.29% |
| 2015 | CA$59.49 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Aequus Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $479.73K USD |
| MoneyControl | $479.73K USD |
| MarketWatch | $479.73K USD |
| marketcap.company | $479.73K USD |
| Reuters | $479.73K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more